Alseres Pharmaceuticals (Alseres Pharmaceuticals) LT-Debt-to-Total-Asset : 29.74 (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Alseres Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jun. 2014 was 29.74.

Alseres Pharmaceuticals's long-term debt to total assets ratio declined from Jun. 2013 (108.11) to Jun. 2014 (29.74). It may suggest that Alseres Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Alseres Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Alseres Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals LT-Debt-to-Total-Asset Chart

Alseres Pharmaceuticals Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.07

16.56

20.31

Alseres Pharmaceuticals Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															108.11	116.79	20.31	22.33	29.74

Alseres Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Alseres Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as

LT Debt to Total Assets (A: Dec. 2013 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2013 )	/	Total Assets (A: Dec. 2013 )
	=	7.82	/	0.385
	=	20.31

Alseres Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2014 is calculated as

LT Debt to Total Assets (Q: Jun. 2014 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2014 )	/	Total Assets (Q: Jun. 2014 )
	=	8.297	/	0.279
	=	29.74

Alseres Pharmaceuticals (OTCPK:ALSE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Alseres Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466

Website

http://www.alseres.com

Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.

Executives

Mark Jerome Pykett	officer: President and COO	223A MAIN ST, BOXFORD MA 021921
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Peter G Savas	director, officer: Chief Executive Officer	110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston	director	C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr	officer: Exec VP of Fin & Admin & CFO	C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon	officer: Chief Financial Officer	1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck	director	P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines

From GuruFocus

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-14-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009